/HCWB
HCWB Stock - HCW Biologics Inc.
Healthcare|BiotechnologyNASDAQ
$1.57-3.68%
$0.06 (-3.68%) • Dec 19
53
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.93
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.73
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for HCWB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.55 – $1.59
TARGET (TP)$1.81
STOP LOSS$1.44
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.67
52W High$41.20
52W Low$1.52
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.57M | $2.84M | $6.72M | N/A | $4.10M |
| Gross Profit | $959,403 | $560,360 | $2.59M | $-543,598 | $4.10M |
| Gross Margin | 37.4% | 19.7% | 38.5% | N/A | 100.0% |
| Operating Income | $-29,479,667 | $-25,717,160 | $-15,078,778 | $-13,367,834 | $-5,824,525 |
| Net Income | $-30,023,814 | $-24,994,277 | $-14,900,703 | $-12,862,468 | $-5,779,877 |
| Net Margin | -1169.7% | -879.5% | -221.7% | N/A | -141.0% |
| EPS | $-0.77 | $-0.70 | $-0.41 | $-0.35 | $-0.16 |
Company Overview
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
HCWBBeat Rate
29%
Last 14 quarters
Avg Surprise
-91.3%
EPS vs Estimate
Beats / Misses
4/9
1 met exactly
Latest EPS
$-2.02
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
-106.9%
$-0.30vs$-0.14
Q3 24
-122.2%
$-0.40vs$-0.18
Q4 24
+23.1%
$-0.10vs$-0.13
Q1 25
-188.9%
$-3.20vs$3.60
Q2 25
No data
Q3 25
-477.2%
$-6.79vs$1.80
Q4 25
-227.8%
$-2.02vs$1.58
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 14, 2025 | $1.58 | $-2.02 | -227.8% | ✗ MISS |
Q3 2025 | Aug 18, 2025 | $1.80 | $-6.79 | -477.2% | ✗ MISS |
Q2 2025 | May 15, 2025 | — | $-0.05 | — | — |
Q1 2025 | Mar 28, 2025 | $3.60 | $-3.20 | -188.9% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | $-0.13 | $-0.10 | +23.1% | ✓ BEAT |
Q3 2024 | Aug 14, 2024 | $-0.18 | $-0.40 | -122.2% | ✗ MISS |
Q2 2024 | Apr 1, 2024 | $-0.14 | $-0.30 | -106.9% | ✗ MISS |
Q1 2024 | Mar 26, 2024 | — | $-0.15 | — | — |
Q4 2023 | Nov 14, 2023 | $-0.13 | $-0.14 | -7.7% | ✗ MISS |
Q3 2023 | Aug 11, 2023 | $-0.15 | $-0.12 | +20.0% | ✓ BEAT |
Q2 2023 | May 9, 2023 | $-0.14 | $-0.14 | 0.0% | = MET |
Q1 2023 | Mar 28, 2023 | $0.16 | $-0.15 | -193.8% | ✗ MISS |
Q4 2022 | Nov 7, 2022 | $-0.12 | $-0.14 | -16.7% | ✗ MISS |
Q3 2022 | Aug 12, 2022 | $-0.12 | $-0.10 | +16.7% | ✓ BEAT |
Q2 2022 | May 13, 2022 | $-0.11 | $-0.06 | +45.5% | ✓ BEAT |
Q1 2022 | Mar 29, 2022 | $-0.12 | $-0.17 | -41.7% | ✗ MISS |
Q4 2021 | Nov 12, 2021 | — | $-0.14 | — | — |
Q3 2021 | Aug 13, 2021 | — | $-0.08 | — | — |
Q3 2021 | Jul 21, 2021 | — | $-0.08 | — | — |
Q4 2020 | Dec 31, 2020 | — | $0.07 | — | — |
Latest News
HCW Biologics Announces $4M Offering Of ~168K Common Shares, Warrants At Amended Exercise Price Of $2.66 To Buy 1.3M Common Shares
➖ NeutralBenzinga•Nov 19, 2025, 01:34 PM•Also:
HCW Biologics Doses First Participant At Its Clinical Study Evaluating HCW9302 In Patients With Alopecia Areata
📈 PositiveBenzinga•Nov 18, 2025, 12:26 PM
HCWB stock has given up its prior loss. HCW Biologics shares were trading lower after the company reported mixed Q3 financial results.
➖ NeutralBenzinga•Nov 17, 2025, 05:43 PM
HCW Biologics shares are trading lower after the company reported mixed Q3 financial results. Also, the company announced it believed substantial doubt exists regarding its ability to continue as a growing concern.
📉 NegativeBenzinga•Nov 17, 2025, 02:07 PM
HCW Biologics Says Company Believes "substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the issuance date of the audited financial statements, without additional funding or financial support."
📉 NegativeBenzinga•Nov 14, 2025, 09:48 PM
HCW Biologics Q3 EPS $(2.02) Misses $1.58 Estimate, Sales $15.606M Beat $7.000M Estimate
➖ NeutralBenzinga•Nov 14, 2025, 09:47 PM
HCW Biologics Highlights HCW11-040 Data Presented At 40th Annual Meeting of the Society for Immunotherapy of Cancer
📈 PositiveBenzinga•Nov 10, 2025, 12:08 PM
HCW Biologics Unveils New Cancer Therapy Designed to 'Reawaken' Immune Cells to Fight Solid Tumors
📈 PositiveBenzinga•Nov 7, 2025, 12:09 PM
HCW Biologics Scientists Develop Tissue Factor-Targeting T-Cell Engagers Against Solid Tumors, Constructed With Proprietary TRBC Product Discovery And Development Platform Technology
📈 PositiveBenzinga•Sep 9, 2025, 12:02 PM
HCW Biologics, Inc. Awarded Patent Number US 12398189 B2 For "Methods of activating regulatory T cells"
📈 PositiveBenzinga•Aug 26, 2025, 08:01 PM
HCW Biologics Shares Resume Trade Following Circuit Breaker Halt
➖ NeutralBenzinga•Aug 25, 2025, 01:50 PM
HCW Biologics shares are trading higher after the company announced its scientists have developed pembrolizumab-based immunotherapeutics against solid tumors.
📈 PositiveBenzinga•Aug 25, 2025, 12:18 PM
HCW Biologics Announces Breakthrough In Second-Generation Pembrolizumab-Based Immunotherapy For Solid Tumors, Showing Enhanced Immune Activation And Tumor Infiltration
📈 PositiveBenzinga•Aug 25, 2025, 12:08 PM
HCW Biologics Q2 EPS $(6.79) Misses $1.80 Estimate, Sales $6.550K Miss $7.000M Estimate
📉 NegativeBenzinga•Aug 18, 2025, 06:46 PM
Hcw Biologics Revenue Plunges 98 Percent
📉 NegativeThe Motley Fool•Aug 14, 2025, 10:33 PM
HCW Biologics regains compliance with Nasdaq Capital Market requirements
📈 PositiveSeeking Alpha•Jun 26, 2025, 12:00 PM
HCW Biologics jumps 16% on pricing $5M follow on offering
📈 PositiveSeeking Alpha•May 14, 2025, 07:14 AM
Frequently Asked Questions about HCWB
What is HCWB's current stock price?
HCW Biologics Inc. (HCWB) is currently trading at $1.57 per share. The stock has moved -3.68% today.
What is the analyst price target for HCWB?
No analyst price targets are currently available for this stock.
What sector is HCW Biologics Inc. in?
HCW Biologics Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is HCWB's market cap?
HCW Biologics Inc. has a market capitalization of $0.00 billion, making it a small-cap company.
Does HCWB pay dividends?
No, HCW Biologics Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACXP
Acurx Pharmaceuticals, Inc.
$3.33
Mkt Cap: $0.0B
ADIL
Adial Pharmaceuticals, Inc.
$0.24
Mkt Cap: $0.0B
APRE
Aprea Therapeutics, Inc.
$0.93
Mkt Cap: $0.0B
APVO
Aptevo Therapeutics Inc.
$1.07
Mkt Cap: $0.0B
BCDA
BioCardia, Inc.
$1.27
Mkt Cap: $0.0B
BCLI
Brainstorm Cell Therapeutics Inc.
$0.56
Mkt Cap: $0.0B
CELZ
Creative Medical Technology Holdings, Inc.
$2.11
Mkt Cap: $0.0B
INAB
IN8bio, Inc.
$1.21
Mkt Cap: $0.0B
NRSN
NeuroSense Therapeutics Ltd.
$0.81
Mkt Cap: $0.0B
RNAZ
TransCode Therapeutics, Inc.
$7.92
Mkt Cap: $0.0B
Explore stocks similar to HCWB for comparison